Latest news
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Debiopharm and ThinkingNodeLife.ai Forge Strategic Partnership to Propel Cancer Drug Development
MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment
Debiopharm Extends SunRock Biopharma Partnership for Antibody-Drug Conjugates Targeting HER3 in EGFR Mutated Cancers
Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
Le 8e Challenge Qualité de vie du patient récompense BOOTIS.CH, plateforme d’organisation de voyages pour les personnes souffrant d’un handicap
Debiopharm invests over 30 million on innovation when its workforce jumped 33% in Valais in one year
Transfer of Marketing Authorization of Anticancer Drug Elplat® to Takata Pharmaceutical
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.